This week, James Stevenson, PharmD, FASHP, professor at the University of Michigan College of Pharmacy, delivered a webinar via the Academy of Managed Care Pharmacy.
This week, James Stevenson, PharmD, FASHP, professor at the University of Michigan College of Pharmacy, delivered a webinar via the Academy of Managed Care Pharmacy. The outset of the webinar focused on familiarizing pharmacists with key facts concerning biosimilars, including the following:
Dr Stevenson also discussed the role of clinical trials for biosimilars, explaining that:
Finally, the webinar addressed the issue of biosimilar interchangeability. Dr Stevenson stressed that the fact that no biosimilars have been deemed interchangeable to date does not indicate that these products are inferior to their references; instead, he said, because the FDA has not yet finalized its guidance on demonstrating interchangeability, there exists no path via which a biosimilar could achieve interchangeable status. He highlighted several important factors that will impact the eventual interchangeability of biosimilars, including the following:
Dr Stevenson said that recent reviews of the literature concerning anti-tumor necrosis factor (anti-TNF) biosimilars support the interchangeability of biosimilar products, and noted that many companies have included at least a single switching arm in their biosimilar trials, even in the absence of FDA guidance. Dr Stevenson's remarks echo those of FDA representatives who have suggested that biosimilars could begin to receive interchangeable designations within the next 2 years.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.